Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02813265
Other study ID # KPI-121-C-006
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 2016
Est. completion date October 2017

Study information

Verified date January 2021
Source Kala Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).


Description:

This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.


Recruitment information / eligibility

Status Completed
Enrollment 918
Est. completion date October 2017
Est. primary completion date October 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have a documented clinical diagnosis of dry eye disease in both eyes Exclusion Criteria: - Known hypersensitivity or contraindication to the investigational product(s) or components - History of glaucoma, Intraocular Pressure (IOP) >21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye. - Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within 30 days prior to screening. - In the opinion of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.

Study Design


Intervention

Drug:
KPI-121 0.25% Ophthalmic Suspension

Vehicle of KPI-121 0.25% Ophthalmic Suspension


Locations

Country Name City State
United States Dixon Eye Care Albany Georgia
United States Sall Research Medical Center Artesia California
United States Chu Vision Institute Bloomington Minnesota
United States Florida Eye Microsurgical Institute, Inc. Boynton Beach Florida
United States Hill Country Eye Center Cedar Park Texas
United States Mundorf Eye Center Charlotte North Carolina
United States Lifelong Vision Foundation at Pepose Vision Institute Chesterfield Missouri
United States Abrams Eye Center Cleveland Ohio
United States Opthalamic Surgeons & Consultants of Ohio Columbus Ohio
United States Scott & Christie and Associates, PC Cranberry Township Pennsylvania
United States Firozvi Research, LLC / North Carolina Eye, Ear, Nose & Throat Durham North Carolina
United States Bergstrom Eye Research Fargo North Dakota
United States Eye Center of Northern Colorado, PC Fort Collins Colorado
United States Eye Associates of Fort Myers Fort Myers Florida
United States Orange County Ophthalmology Medical Group Garden Grove California
United States The Eye Center of Southern CT, P.C. Hamden Connecticut
United States Houston Eye Associates Houston Texas
United States Midwest Cornea Associates, LLC Indianapolis Indiana
United States United Medical Research Institute Inglewood California
United States Jacksoneye, S. C. Lake Villa Illinois
United States Conestoga Eye Lancaster Pennsylvania
United States Shettle Eye Research, Inc. Largo Florida
United States Wellish Vision Institute Las Vegas Nevada
United States Tanner Clinic Layton Utah
United States The Eye Clinic of Texas, Affiliate of Houston Eye Associates League City Texas
United States Lake Travis Eye and Laser Center Leander Texas
United States Eyecare Arkansas, P.A. Little Rock Arkansas
United States Little Rock Eye Clinic, LLP Little Rock Arkansas
United States Corneal Consultants of Colorado Littleton Colorado
United States Apex Eye Mason Ohio
United States See Clearly Vision McLean Virginia
United States Total Eye Care, PA Memphis Tennessee
United States North Valley Eye Medical Group Mission Hills California
United States Montebello Medical Center, Inc. Montebello California
United States LoBue Laser and Eye Medical Center Murrieta California
United States Eye Research Foundation Newport Beach California
United States Virginia Eye Consultants Norfolk Virginia
United States Pendleton Eye Center Oceanside California
United States Stiles EyeCare Excellence and Glaucoma Institute Overland Park Kansas
United States Atlantic Eye Center Palm Coast Florida
United States The Eye Center of North Florida Panama City Florida
United States Matossian Eye Associates Pennington New Jersey
United States North Bay Eye Associates, Inc. Petaluma California
United States Cornea and Cataract Consultants of Arizona Phoenix Arizona
United States UPMC Eye Center Pittsburgh Pennsylvania
United States Eyecare Center Raleigh North Carolina
United States Martel Eye Medical Group Rancho Cordova California
United States Black Hills Regional Eye Institute Rapid City South Dakota
United States Rochester Ophthalmological Group, PC Rochester New York
United States Roseburg Research Associates, LLC Roseburg Oregon
United States Sacramento Eye Consultants Sacramento California
United States Ophthalmology Associates Saint Louis Missouri
United States Ophthalmology Consultants, Ltd. Saint Louis Missouri
United States Eye Clinics of South Texas San Antonio Texas
United States Keystone Research - Medical Center Ophthalmology Associates San Antonio Texas
United States R and R Eye Research, LLC San Antonio Texas
United States Schwartz Laser Eye Center Scottsdale Arizona
United States Cornea Consultants of Albany Slingerlands New York
United States South Shore Eye Center, LLP Wantagh New York
United States Clinical Eye Research of Boston Winchester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Kala Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15) Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe. Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Primary Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse. Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Primary Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15) Comparison of mean corneal fluorescein staining between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using methods developed by the National Eye Institute (NEI) Dry Eye Workshop in evaluating 5 regions of the cornea (superior, inferior, nasal, temporal and central) using a 0-3 grading scale, where 0 = no visible staining, 1 = Mild, 2 = moderate and 3 = severe. Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Primary Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline. Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Secondary Change in Conjunctival Hyperemia Scores at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort at Baseline (Day 1) Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe. Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Secondary Proportion of Subjects With =1 Improvement in Conjunctival Hyperemia at Visit 4 (Day 15) Proportion of subjects with =1 improvement from baseline in conjunctival hyperemia scores. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe. Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Secondary Change From Baseline/Visit 2 (Day 1) Conjunctival Hyperemia Scores at Visit 4 (Day 15) for the Mean of All Regions (Nasal, Temporal, Frontal) Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe. Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Secondary Change in Ocular Discomfort Severity Scores Prior to Visit 3 (Day 8) Minus the Mean of the Scores to Baseline/Visit 2 (Day 1) Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse. Baseline/Visit 2 (Day 1) and to Visit 3 (Day 8)
Secondary Change in Ocular Discomfort Severity Scores Prior to Visit 3 (Day 8) Minus Baseline/Visit 2 (Day 1) in the Subgroup of Participants With More Severe Ocular Discomfort. Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse. Baseline/Visit 2 (Day 1) and to Visit 3 (Day 8)
Secondary Change in Ocular Discomfort Severity Scores on Day 4 (Diary) Minus Baseline/Visit 2 (Day 1) Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse. Baseline/Visit 2 (Day 1) and to Visit 3 (Day 8)
Secondary Change in Ocular Discomfort Severity Scores on Day 4 Day 4 (Diary) Minus Baseline/Visit 2 (Day 1) in the Subgroup of Participants With More Severe Ocular Discomfort Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline. Baseline/Visit 2 (Day 1) and to Visit 3 (Day 8)
Secondary Change From Baseline/Visit 2 (Day 1) in Conjunctival Hyperemia Scores With a Day 1 Conjunctival Hyperemia Score of = 2 in the Subgroup of Participants With More Severe Ocular Discomfort Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale in a sub-group of participants with more severe ocular discomfort at baseline.. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe. Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Secondary Subjects With a Grade of 0 in Conjunctival Hyperemia Score at Visit 4 (Day 15) Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe Visit 4 (Day 15)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Recruiting NCT04701086 - 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis N/A
Active, not recruiting NCT03697876 - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel Phase 1
Terminated NCT02815293 - Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase 3
Completed NCT02910713 - Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation N/A
Completed NCT04104997 - A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers Phase 1
Recruiting NCT02595606 - 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Phase 4
Completed NCT01711424 - An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease N/A
Completed NCT01202747 - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Phase 2/Phase 3
Completed NCT01015209 - Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers Phase 1
Completed NCT00969280 - Acupuncture for Dry Eye Syndrome Phase 3
Completed NCT00739713 - Effects of Sea Buckthorn Oil on Dry Eye N/A
Completed NCT00756678 - Efficacy and Acceptability of Two Lubricant Eye Drops Phase 4
Completed NCT01496482 - Comparison of Evaporimetry With the Established Methods of Tear Film Measurement N/A
Completed NCT00370747 - Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome Phase 2
Completed NCT00349440 - Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Phase 4
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Completed NCT02871440 - A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye Phase 3
Completed NCT05042960 - Computer Screen Properties Study N/A